Candriam SCA’s Fortress Biotech FBIO Stock Holding History

Candriam SCA’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,500	Closed	-$80K	–	887
2021 Q2	$80K	Hold	1,500	–	–	﹤0.01%	849
2021 Q1	$68K	Hold	1,500	–	–	﹤0.01%	773
2020 Q4	$71K	Hold	1,500	–	–	﹤0.01%	787
2020 Q3	$91K	Hold	1,500	–	–	﹤0.01%	774
2020 Q2	$60K	Hold	1,500	–	–	﹤0.01%	777
2020 Q1	$57K	Hold	1,500	–	–	﹤0.01%	767
2019 Q4	$58K	Hold	1,500	–	–	﹤0.01%	786
2019 Q3	$32K	Hold	1,500	–	–	﹤0.01%	741
2019 Q2	$34K	Buy	+1,500	New	+$38.6K	﹤0.01%	807

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Candriam SCA's FBIO Position: Q3 2021 in Review

Candriam SCA sold out of Fortress Biotech (FBIO) in Q3 2021, closing a stake of 1,500 shares — an estimated $80K sold.

Candriam SCA first reported a position in FBIO in Q2 2019 and held it in 9 quarters. The position peaked at $91K in Q3 2020. 79 funds tracked by Wall St. Rank hold FBIO as of Q3 2021.

Candriam SCA reported no remaining Fortress Biotech position as of Q3 2021 after selling out during the quarter.
Candriam SCA sold 1,500 Fortress Biotech shares in Q3 2021, an estimated $80K.
Candriam SCA first reported a position in Fortress Biotech in Q2 2019 and held it in 9 quarters.
Candriam SCA's Fortress Biotech position peaked at $91K in Q3 2020.
79 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.